Cyprotex PLC Director Dealing (4645A)
December 22 2014 - 7:12AM
UK Regulatory
TIDMCRX
RNS Number : 4645A
Cyprotex PLC
22 December 2014
Cyprotex PLC
("Cyprotex" or "the Company")
Director dealing
The Company received notification that Ralph Stephen Harris,
Non-executive Director of the Company, acquired 25,000 ordinary
shares in the Company on 19 December 2014 at a price of 42.5 pence
per share. As a result of this purchase Mr. Harris has a beneficial
interest in 235,514 ordinary shares in the Company representing
approximately 1.05 per cent. of the Company's total voting
rights.
Cyprotex PLC
Tel : +44 (0)1625
505 100
Dr Anthony Baxter, Chief Executive
Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
ir@cyprotex.com www.cyprotex.com
N + 1 Singer (NOMAD and broker to Tel : +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson
shaun.dobson@n1singer.com
Jen Boorer
jen.boorer@n1singer.com www.nplus1singer.com
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites in Macclesfield, near Manchester in
the UK, Watertown, MA and Kalamazoo, MI in the US. The Company was
established in 1999 and works with more than 1,000 partners within
the pharmaceutical and biotech industry, cosmetics and personal
care industry and the chemical industry. Cyprotex acquired Apredica
and the assets of Cellumen Inc. in August 2010 and the combined
business provides support for a wide range of experimental and
computational ADME-Tox and PK services, extending from early drug
discovery through to IND submission. The acquisition of the assets
and business of CeeTox in January 2014 has enabled Cyprotex to
expand its range of services to target the personal care, cosmetics
and chemical industries. The Company's core capabilities include
high quality in vitro ADME screening services, mechanistic
toxicology and high content toxicology screening services,
including our proprietary CellCiphr(R) toxicity prediction
technology, predictive modelling using PBPK and QSAR techniques,
including Cloe(R) PK for in vivo PK prediction, and a range of
skin, ocular and endocrine disruption services. For more
information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSPGGMUPUPCGPP
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024